Skip to main content
Equibles
KPTI logo

KPTI · Karyopharm Therapeutics Inc.

Track KPTI — free Ask ALVIS about KPTI
$1.92 +0.01 (+0.26%)
Going-concern doubt — flagged May 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”
View the 10-Q filed May 14, 2026
Market Cap
$43.29M
Shares
22.66M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.91 Open$1.95 Day$1.88–2.06 52W$1.80–10.99 Avg vol 30d1.8M Short int6.3M · 27.9% float · 17.1d Short vol58% Last earningsJun 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · May 14

Up next

Next earnings call
Sep 7, 2026 Est · unconfirmed · in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 14, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
      Market backdrop VIX 15.8 · calm Equity put/call 0.46
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −75%
      below
      Price vs 50-day avg −77%
      below
      RSI (14) 16
      oversold
      MACD trend Negative
      52-week position 1%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −82%
      trailing
      6-month return −74%
      trailing
      YTD return −74%
      this year
      Relative strength −85%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $8 › 200d $8 — 50d above 200d
      Institutional flow Accumulating
      13 of 84 funds reported for Jun 30 · net +52.7K sh shares · +5 new
      Insider flow Distributing
      Net -$36.1K over 90 days · 100% sells
      Short interest Falling
      27.85% of float · ▼ -4.1% MoM · 17.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      84 holders — mid 3-yr range
      Squeeze score 75
      high risk · 0–100
      Fundamentals
      Poor
      Revenue growth +1%
      Y/Y
      EPS growth −28%
      Y/Y
      Free cash flow $-75.4M
      Balance sheet $108.8M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 118%
      annualized · 1-yr
      Max drawdown −82%
      past year
      ATR 46.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 14, 2026
      full year 2026
      Total revenue Initiated $130M – $150M
      prior FY $146.07M midpoint −4.2% Y/Y
      Full-Year 2026
      U.S. XPOVIO Net Product Revenue Initiated $115M – $130M
      Guided vs delivered · last 1 settled
      Net product revenue full year 2025
      guided $110M – $120M
      $146.07M Beat +27.0%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −75% Bearish
      Price vs 50-day avg
      −77% Bearish
      RSI (14)
      16 Neutral
      MACD trend
      Negative Bearish
      52-week position
      1% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $8 › 200d $8 — 50d above 200d
      Institutional flow Accumulating
      13 of 84 funds reported for Jun 30 · net +52.7K sh shares · +5 new
      Insider flow Distributing
      Net -$36.1K over 90 days · 100% sells
      Short interest Falling
      27.85% of float · ▼ -4.1% MoM · 17.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      84 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $2 Now $2 · 1% 52-wk high $11
      vs 200-day avg -75% vs 50-day avg -77%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Royalty revenue $1.9M first quarter of 2026 —
      Cash, cash equivalents, restricted cash and investments $64M as of December 31, 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      KPTI
      Karyopharm Therapeutics Inc.
      this stock
      		$43.29M -74.0% +0.6% — 27.9%
      ONC
      BeOne Medicines Ltd.
      		 $484.13B +7.8% +22179.2% 744.4 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $122.89B +6.9% +46.2% 28.2 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $79.13B -0.2% +20.8% 19.0 3.4%
      ARGX
      Argenx SE
      		 $54.30B +3.2% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      89
      % held
      112.1%
      Reported
      13 of 84
      Top holder
      Commodore Capital LP
      Held Float
      View
      Held by Funds
      Fund positions
      22
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      6.3M
      Days to cover
      17.1d
      Change
      -271.1K sh
      View
      Short Volume
      Short vol %
      58%
      As of
      Aug 5, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.4K
      Value
      $13.8K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      36.4%
      Week of
      Jun 29, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$36.1K
      Buyers / Sellers
      0 / 6
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $146.1M
      Net income (FY)
      $-196.0M
      EPS diluted
      $-17.93
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 31, 2026
      This year
      14
      View
      Exempt Offerings
      Offering
      $165.0M
      Filed
      Dec 8, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      KPTI -72.2% -82.1% -74.1% -0.5% -74.1%
      SPY +5.5% +3.3% +11.3% +3.1% +12.9%
      vs SPY -77.7% -85.4% -85.3% -3.6% -86.9%
      Key facts CIK 1503802 CUSIP 48576U205 13F (30d) 14 filings 14 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)